The two Pan-Asian Guideline Adaptations of parental ESMO Clinical Practice Guidelines reflect the younger age of disease occurrence and lack of some treatment data in Asia
Novel approaches including the use of a JAK-STAT inhibitor, a nomogram and assessment of eosinophil proportions are presented for improving the management of immune-related adverse events
In an early-phase study, the selective inhibitor nanatinostat was well tolerated with evidence of antitumour activity in combination with antiviral therapy
Addressing cost and affordability issues is now key to increasing the use of this approach in the clinical setting in Asia
Several ESMO initiatives highlight the need for closing the gap between fast cancer research and a lack of accessibility to treatments in the real world
Data from the IMbrave050 study show benefits of atezolizumab plus bevacizumab in terms of disease recurrence, but long-term data are needed
Increasing data show that they are indicators of inequitable environments which may negatively impact on cancer outcomes, but more efforts are needed to properly assess them in oncology
In the IND227 trial, more pronounced benefits of the immunotherapy were observed in patients with non-epithelioid histology and regardless of PD-L1 status
Green oriented practical tips encompass a reorganisation of waste disposal and pathology testing at single centres which may result in a reduction of the carbon footprint of cancer care globally
Promising data are reported for tumours with dMMR, MSI-H and rare POLE alterations, reinforcing the role of molecular testing for tissue-agnostic treatment
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.